
























































































Identifying incipient dementia individual use machine learn and amyloid image 


lable at ScienceDirect 

Neurobiology of Aging xxx (2017) 1e11 
Contents list avai 
Neurobiology of Aging 

journal homepage: www.elsevier .com/locate/neuaging 
Identifying incipient dementia individual use machine learn 
and amyloid image 

Sulantha Mathotaarachchi a,b, Tharick A. Pascoal a, Monica Shin a, Andrea L. Benedet a, 
Min Su Kang a, Thomas Beaudry a, Vladimir S. Fonov b, Serge Gauthier c,d,e, f, 
Pedro Rosa-Neto a,b,c,d,e, f,*, for the Alzheimer’s Disease Neuroimaging Initiative1 

a Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging (MCSA), Douglas Research Institute, McGill University, 
Montreal, Quebec, Canada 
bMcConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada 
cMcGill University Research Centre for Studies in Aging (MCSA), Douglas Research Institute, McGill University, Montreal, Quebec, Canada 
dDouglas Research Institute, McGill University, Montreal, Quebec, Canada 
eDepartment of Psychiatry, McGill University, Montreal, Quebec, Canada 
fDepartment of Neurology & Neurosurgery, McGill University, Montreal, Quebec, Canada 
a r t i c l e i n f o 

Article history: 
Received 6 March 2017 
Received in revise form 20 June 2017 
Accepted 30 June 2017 

Keywords: 
Alzheimer’s disease 
Mild cognitive impairment 
Prediction 
Amyloid 
Random forest 
Random under sample 
* Corresponding author at: Translational Neuro 
University Research Centre for Studies in Aging, 6875 L 
Montreal, Québec H4H 1R3, Canada. Tel.: þ1 514 766- 

E-mail address: pedro.rosa@mcgill.ca (P. Rosa-Neto 
1 Data use in preparation of this article be ob 

Disease Neuroimaging Initiative (ADNI) database (ad 
investigator within the ADNI contribute to the de 
ADNI and/or provide data but do not participate i 
report. A complete listing of ADNI investigator can be 
edu/wp-content/uploads/how_to_apply/ADNI_Acknow 

0197-4580/� 2017 The Author(s). Published by Elsevier 
http://dx.doi.org/10.1016/j.neurobiolaging.2017.06.027 
a b s t r a c t 

Identifying individual destine to develop Alzheimer’s dementia within time frame acceptable for 
clinical trial constitutes an important challenge to design study to test emerge disease-modifying 
therapies. Although amyloid-b protein be the core pathologic feature of Alzheimer’s disease, bio- 
marker of neuronal degeneration be the only one believe to provide satisfactory prediction of 
clinical progression within short time frames. Here, we propose a machine learningebased probabilistic 
method design to ass the progression to dementia within 24 months, base on the regional in- 
formation from a single amyloid positron emission tomography scan. Importantly, the propose method 
be design to overcome the inherent adverse imbalance proportion between stable and progressive 
mild cognitive impairment individual within a short observation period. The novel algorithm obtain 
an accuracy of 84% and an under-receiver operating characteristic curve of 0.91, outperform the 
exist algorithm use the same biomarker measure and previous study use multiple biomarker 
modalities. With it high accuracy, this algorithm have immediate application for population enrichment 
in clinical trial design to test disease-modifying therapy aim to mitigate the progression to 
Alzheimer’s disease dementia. 
� 2017 The Author(s). Published by Elsevier Inc. This be an open access article under the CC BY-NC-ND 

license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 
1. Introduction 

Alzheimer’s disease be the most common form of dementia, ac- 
counting for approximately 60%e80% of the case with alarm 
economic and social cost (Pouryamout et al., 2012). It be well un- 
derstood that Alzheimer’s disease pathophysiology follow a 
image Laboratory, McGill 
a Salle Blvd - FBC room 3149, 
2010; fax: þ1 514 888-4050. 
). 
tained from the Alzheimer’s 
ni.loni.usc.edu). As such, the 
sign and implementation of 
n analysis or write of this 
found at: http://adni.loni.usc. 
ledgement_List.pdf. 

Inc. This be an open access article 
gradual course with pathology develop over decade before 
symptom onset (Braak and Braak, 1991; Mosconi et al., 2007). Thus, 
there be an increase interest to advance the disease-modifying 
clinical trial to the predementia stage of Alzheimer’s disease 
give the good chance of obtain tangible disease-modifying 
effects. This have be encourage by the identification of bio- 
marker to detect the pathologic signature at the early stage of the 
disease (Buerger et al., 2006; Fagan et al., 2006;McEvoy and Brewer, 
2010; Morris et al., 2009). However, give the high prevalence of 
cognitively normal elderly individual carry the Alzheimer’s 
disease pathophysiology, accurately identify individual who be 
in the early stage of Alzheimer’s disease have be a significant 
challenge. Thus, the development of effective clinical trial have be 
severely hamper by not be able to recruit individual who 
have a high likelihood of develop Alzheimer’s disease (Holland 
et al., 2012) within a time period acceptable to conduct a study. 
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 

Delta:1_given name 
Delta:1_surname 
Delta:1_given name 
Delta:1_surname 
Delta:1_given name 
Delta:1_surname 
Delta:1_given name 
Delta:1_surname 
Delta:1_given name 
http://creativecommons.org/licenses/by-nc-nd/4.0/ 
mailto:pedro.rosa@mcgill.ca 
http://adni.loni.usc.edu 
http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf 
http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf 
www.sciencedirect.com/science/journal/01974580 
http://www.elsevier.com/locate/neuaging 
http://creativecommons.org/licenses/by-nc-nd/4.0/ 
http://dx.doi.org/10.1016/j.neurobiolaging.2017.06.027 
http://dx.doi.org/10.1016/j.neurobiolaging.2017.06.027 
http://dx.doi.org/10.1016/j.neurobiolaging.2017.06.027 


S. Mathotaarachchi et al. / Neurobiology of Aging xxx (2017) 1e112 
Identification of effective biomarker signature to determine the 
progression of dementia have be a significant challenge to accu- 
rately predict the short-term clinical progression. It be believe that 
the biomarkers of neurodegeneration such a glucose metabolism 
and brain atrophy would be the most effective, a the other path- 
ologic marker such a brain amyloid-b (Ab) deposition and for- 
mation of hyperphosphorylated tau tangle occur year or decade 
before the symptom onset (Jack et al., 2010a,b, 2013). However, 
numerous study base on neurodegenerative biomarkers have 
indicate a decrease in the ability to predict the clinical progression 
when the observation time be more than 18 months. Given that the 
accumulation of Ab in the brain be a hallmark characteristic of 
Alzheimer’s disease, amyloid-based biomarkers can be assume to 
provide a good sensitivity to Alzheimer’s disease pathology over a 
longer observation period (Trzepacz et al., 2014). 

Studies conduct to evaluate the utility of amyloid biomarkers 
have use the cerebrospinal fluid (CSF) Ab measurement due to 
the relatively high availability compare with amyloid positron 
emission tomography (PET) biomarkers. These study have often 
combine other CSF measurement such a tau and p-tau concen- 
trations and magnetic resonance image (MRI) biomarkers 
(Apostolova et al., 2014; Davatzikos et al., 2011; Hall et al., 2015; 
Yang et al., 2012; Young et al., 2012) to accommodate for the 
limited dimensionality offer by the CSF measurements. However, 
the possibility to regionally ass Alzheimer’s disease pathophys- 
iology and the increase availability of amyloid PET image in large- 
scale age study have enable the evaluation of this image 
biomarker a a diagnostic tool. 

As the early detectable clinical stage of the trajectory toward 
dementia, mild cognitive impairment (MCI) provide an attractive 
point of entry to disease-modifying intervention (Markesbery, 
2010). However, not all MCI individual carry Alzheimer’s disease 
pathophysiology and progress to Alzheimer’s disease in an optimal 
time frame for clinical trial. Thus, identification of biomarker sig- 
nature of MCI individual on the verge of progression to dementia 
and predict the likelihood of conversion have immediate appli- 
cation in disease-modifying clinical trial by include those in- 
dividuals with high likelihood to progress. This will increase the 
statistical power of the clinical trial by reduce false positive and 
would directly impact the associate costs. Furthermore, these in- 
formationwould also provide important prognostic information for 
the patient and their family to plan and manage treatment and 
care (Gelosa and Brooks, 2012). 

The prediction of the clinical progression to dementia from MCI 
phase constitutes a challenge due to the considerably low number 
of progressive MCI (pMCI) individual compare with the stable MCI 
(sMCI) individuals, invariably create imbalanced class (pMCI and 
sMCI). In a classification study, if the number of sample from a class 
(sMCI) greatly outnumbers the other class (pMCI), the classifier 
tends to favor the over-representedmajority class (sMCI) by ignore 
the incorrect prediction in theminority class (pMCI). This constitutes 
a challenge know a the “class imbalance problem” and lead to 
decrease sensitivity of the prediction, which have be currently 
overlook in Alzheimer’s disease research. While there be a num- 
ber of technique developed to address this challenge, such a class 
weight adjusting, oversampling the minority class, and under- 
sample themajority class (Japkowicz and Stephen, 2002), the latter 
be identify to perform the best (Seiffert et al., 2008, 2010). Random 
under sample (RUS) be a method of under sampling, which will 
train each of it base learner with the full minority class and a 
randomly under sample majority class. By do this, each base 
learner be trainedwith a balance set of sample from both pMCI and 
sMCI classes, remove the bias toward any particular class. 

Amyloid PET image use in the study be [18F]Florbetapir PET 
scan acquire from the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI). The study cohort present a pMCI rate of 15.75%, 
similar to the rate present by other cohort study and com- 
munity study (Mitchell and Shiri-Feshki, 2009). This present the 
aforementioned class-imbalanced challenge. Current study utilizes 
RUS to overcome this challenge. The novel prediction algorithm be 
present a RUS random forest (RUSRF) and be use to evaluate the 
utility of amyloid PET a a diagnostic tool. 

The present study aim to evaluate the utility of amyloid PET 
image a an early detection tool for individual in the Alzheimer’s 
disease pathway. Specifically, we aim to predict if an MCI individual 
will progress to Alzheimer’s disease or remain MCI within a time 
period of 24 month base on the amyloid PET measurement at 
baseline. We further believe that the propose technique can be 
use to complement the multibiomarker enrichment strategy for 
clinical trial (Wolz et al., 2016). 

This novel technique capitalizes on an optimize feature 
extraction method for amyloid PET, and a method for address 
the class imbalance problem in the context of a random forest 
machine learn classifier (Breiman, 2001). We further compare 
the performance of RUSRF with other widely-used prediction al- 
gorithms such a the Support Vector Machine (SVM), L1 and L2 
regularize logistic regression, and random forest. We believe that 
the novel RUSRF algorithm will outperform these widely-used 
prediction algorithm and that the amyloid PET biomarker might 
serve a an important early diagnostic tool in both research and 
clinical environments. 

2. Materials and method 

2.1. Subjects and data acquisition 

Data use in the preparation of this article be obtain from 
the ADNI database. ADNI be launch in 2003 a a public-private 
partnership, lead by Principal Investigator Michael W. Weiner, MD. 
The primary goal of ADNI have be to test whether serial MRI, 
positron emission tomography (PET), other biological markers, and 
clinical and neuropsychological assessment can be combine to 
measure the progression of MCI and early Alzheimer’s disease. 

We select 273 ADNI-GO/2 participant meeting the criterion for 
single-domain or multidomain amnestic MCI and acquire their [18F] 
Florbetapir PET, demographic, APOE4 genotype information and the 
clinical diagnosiswith the correspondingdiagnosis information for the 
subsequent 24-month follow-up visit (mean follow-up time: 
24.37 months, standard deviation: 1.51 months). For PET image pro- 
cessing purposes, the match T1-weighted MRI image be also 
obtained. The eligibility criterion of MCI be participant with mini- 
mental state examination (MMSE) score equal to or great than 24, 
a clinical dementia rating of 0.5, subjective and objectivememory loss, 
normal activity of daily living, and the absence of other neuropsy- 
chiatric disorder include Alzheimer’s disease (Petersen, 2003). 

The subject be categorize into 2 groups, sMCI and pMCI, 
base on the diagnosis on their follow-up visit. If a subject be 
diagnose to be Alzheimer’s disease in the follow-up visit, that 
subject be categorize a pMCI, and if the subject remainedMCI at 
the 24-month follow-up visit, he or she be categorize a sMCI. Of 
the 273 individual use in the study, only 43 (15.75%) individual 
be diagnose a probable Alzheimer’s disease in their follow-up 
visit and be categorize a pMCI. Demographical information of 
the sample of individual use in the study be present in Table 1. 

2.2. Image processing 

The acquire T1-weightedMRI image be process use the 
CIVET image processing pipeline (Ad-Dab’bagh et al., 2006; 
Zijdenbos et al., 2002), where the image underwent non- 



Table 1 
Demographics of subject include in the study and their classification in training 
and test set 

Characteristic sMCI pMCI 

N (273) 230 43 
Age (SD) 71.45 (7.52) 73.25 (7.65) 
Males (females) 135 (95) 23 (20) 
Education(SD) 16.2 (2.71) 15.86 (2.81) 
APOE 4epositive (Neg)*** 81 (149) 33 (10) 
MMSE (SD)*** 28.22 (1.64) 26.91 (1.87) 
Training ðSTrainÞ (pMCI ratio) 161 30 (15.71%) 
Testing ðSTestÞ (pMCI ratio) 69 13 (15.85%) 

Key: MMSE, mini-mental state examination; pMCI, progressive MCI. 
***p < 0.05. 

S. Mathotaarachchi et al. / Neurobiology of Aging xxx (2017) 1e11 3 
uniformity correction (Sled et al., 1998), brain mask (Smith, 
2002), linear and nonlinear registration to the ICBM 152 Tem- 
plate (Fonov et al., 2009; Mazziotta et al., 1995) use the ANIMAL 
(Collins and Evans, 1997; Collins et al., 1995; Robbins et al., 2004) 
image registration algorithm. Downloaded [18F]Florbetapir PET 
image be already preprocessed to perform motion correction 
and to acquire uniform spatial resolution accord to the step 
outline in (online: http://adni.loni.usc.edu/methods/pet-analysis/ 
pre-processing/, Accessed: 28-03-2016). The PET image be then 
register to the subjects’ own T1-weighted MRI image and be 
spatially normalize to the ICBM 152 template. They be then 
normalize for the regional intensity from the cerebellum gray 
matter and the global white matter to generate [18F]Florbetapir PET 
standard uptake value ratio (SUVR) images. 

2.3. Subject classification 

Two set of subject be generate from the total set of in- 
dividuals a training set (STrain) and test set (STest; Table 1). The 
training set be use in the feature selection step and training the 
machine learn algorithm, while the test set be use solely to 
evaluate the performance of the train machine learn algo- 
rithm. Since the test set be not use in the feature selection step 
or in training, we void any bias or adverse effect from “double 
dipping” in the prediction of progression to Alzheimer’s disease. 
The ratio between the sMCI and pMCI individual be preserve in 
both the training set and the test set. 

2.4. Feature selection 

To identify the brain region from where the PET SUVR value 
be read a feature for the predictors, we employ a voxel-wise 
logistic regression analysis use the VoxelStats (Mathotaarachchi 
et al., 2016) toolbox. For each brain voxel, the follow logistic 
function be solved: 

In 
� p 
1� p 

� 
¼ b0 þ b1*½18F�Florbetapir þ b2*Ageþ b3*Gender 

þ b4*APOE4 
where p ¼ probability of progress to Alzheimer’s disease in 
24 months. Then, for each voxel, the scale increase in odds (scaled 
odds ratio) for one standard deviation (s) increase in [18F]Florbe- 
tapir PET SUVR be calculate a follows: 

Odds RatioScaledðORScaledÞ ¼ eb1*s 

Anatomically significant brain region with ORscaled > 1:5 be 
selectedbasedonexpertopinion, andPETSUVR intensity fromthese 
regionswere extract a themeanof a 3�3�3 clusterof voxels. The 
above regional PET SUVR intensity along with age, gender, and 
APOE4 genotype status be fed into the predictor a features. 
2.5. Prediction 

Prediction be perform use the novel algorithm RUSRF 
base on the random forest classifier (Breiman, 2001). The novel 
algorithm us sample technique to trainmultiple random forest 
predictor to calculate the final prediction. The primary goal of the 
present application be to predict progression to Alzheimer’s disease; 
however, the population contains only 15.71% pMCI individuals. 
This constitutes a class imbalance problem with a majority sMCI 
class. In this case, the predictor tend to be bias to predict the 
majority class (sMCI) and to ignore the misclassification in the 
minority class (pMCI) (Yen and Lee, 2009). To overcome this, the 
novel algorithm utilizes a data sample technique name “random 
undersampling,” where the majority class be randomly sample to 
create a pseudo training set with equal proportion in all the clas- 
ses. This technique be closely related to the RUSBoost technique 
(Seiffert et al., 2008); however, the base classifier use in the pre- 
sent study be random forest and the iterative boostingmethod be not 
employ a the random forest classifier us feature bagging to 
achieve independence and randomness. 

In summary, RUSRF algorithm will train K number of random 
forest predictor with individual pseudo training set with equal 
class distributions. The number of minority class sample ðNaÞ in a 
pseudo training set be equal to the total number of minority class 
sample in the original training set. Thus, all K random forest pre- 
dictors be train for all the minority class instances. The number 
of majority class sample be calculate to be a fraction ðf Þ high 
than the number of sample in the minority class. The final prob- 
ability prediction be calculate a the mean probability across all the 
K random forests, and the final prediction be calculate a the final 
probability prediction great than 0.5. 

The implementation of the RUSRF algorithmwas do in Python 
program language use the random forest implementation in 
the scikit-learn library (Online: http://scikit-learn.org/stable/, 
Accessed: 28-04-2016). 
2.6. Performance evaluation and comparison 

The RUSRF algorithm have 2 primary parameter to be optimize 
base on the application, which be the number of random forest 
predictor and the number of decision tree in each of the random 
forest predictor. To estimate the best combination of these 2 pa- 
rameters, we employ a nest cross-validation technique 
(Huttunen et al., 2012; Moradi et al., 2015). The outer cross- 
validation step divide the training set ðSTrainÞ in to 10 subset 
ðSiTrain; i ¼ 1.10Þ preserve the class ratio of the original popu- 
lation (stratified cross validation). In each training step i, SiTrain be 
subdivide (using stratify cross validation) into 10 subset 
ðSijTrain; j ¼ 1.10Þ and be pass to RUSRF algorithm with a tuple 
of parameter (number of random forest predictors, number of 
tree in each predictor) select from a grid of parameter combi- 
nation for training. The best set of parameter be select base 
on the AUC from the internal 10-fold cross validation. The perfor- 
mance of the predictor be then evaluate base on the AUC, ac- 
curacy (number of correct classification divide by the total 
number of sample [in STest]), F1 score (harmonic mean of precision 
and recall), sensitivity (number of correctly classify pMCI subject 
divide by the total pMCI subjects), and specificity (number of 
correctly classify sMCI subject divide by the total sMCI subjects) 
for the original test set ðSTestÞ. These value be calculate base 
on the prediction of each outer cross-validation step i, on the 
test set ðSTestÞ. By evaluate the performance base on the 
original test set ðSTestÞ, we record the true generalization ability of 
the RUSRF predictor. 

http://adni.loni.usc.edu/methods/pet-analysis/pre-processing/ 
http://adni.loni.usc.edu/methods/pet-analysis/pre-processing/ 
http://scikit-learn.org/stable/ 


Fig. 1. Summary of the step follow to train the RUSRF algorithm to predict the progression of dementia. Abbreviations: MCI, mild cognitive impairment; ROC, receiver operating 
characteristic; RUSRF, RUS random forest. 

S. Mathotaarachchi et al. / Neurobiology of Aging xxx (2017) 1e114 
To examine the performance gain from the RUSRF predictor, we 
train 4 other widely-used classifier such a SVM, logistic 
regression with L1 regularization, logistic regression with L2 reg- 
ularization, and random forest (Breiman, 2001) use the same set 
of feature and compare with the performance of RUSRF. Evalu- 
ating the optimum parameter and the performance for these 
widely-used classifier be also do use a nest cross- 
validation a described above. McNemar’s c2 test be perform 
to compare each of the classifier against random predictors. The 
random predictor be developed by training each of the classi- 
fication algorithm with a randomly permute training set to 
disrupt the relationship between the class label and input fea- 
tures. Furthermore, a pair t-test be perform to compare AUC 
and F1 score of the RUSRF predictor against the other 4 predictors, 
while McNemar’s c2 test be use to compare the sensitivity and 
specificity. However, the overall accuracy of each predictor be not 
use a a measure of comparison because it can misinterpret the 
performance when the sample have imbalanced class probabilities. 
The result p value be Bonferroni adjust to correct for 
multiple comparisons. The classification analysis be carry out in 
Python program language use the scikit-learn library and 
the statistical analysis be carry out use the R program 
language. 

In a binary classification, the random forest algorithm performs 
implicit feature selection base on the parameter call “Gini 
importance” (Breiman, 2001), which be calculate a the accumu- 
lated decrease in “Gini impurity iðtÞ”. This be define as; 
iðtÞ ¼ 1� p20 � p21. Here pk ¼ nkn , which be the fraction of the nk 
sample from class k ¼ f0; 1g out of the total n sample at a node t 
in a binary decision tree in random forest. The decrease in Gini 
impurity result from splitting the node by a threshold sa on 
variable a, and send the sample to 2 subnodes, tl and tr , and be 
calculate a D iðtÞ ¼ iðtÞ � pliðtlÞ � priðtrÞ, where pl ¼ nln and 
pr ¼ nrn , the relative sample fraction at node tl and tr . The opti- 
mum split be then determined, which result in the maximum 
decrease in Gini impurity at node t. The accumulation of these 
decrease in Gini impurity for all node t in all tree T in the Forest, 
be know a the Gini importance ðIGÞ for variable a. 

IGðaÞ ¼ 
X 
T 

X 
t 

Diaðt; TÞ 

This measure indicates how often a variable be use for a split 
and how large it discriminative power be in the classification study. 
In the RUSRF algorithm, the mean of this measure across all the 
random forests, K , be use a the measure of feature importance for 
variable a. 

ImportanceðaÞ ¼ 1 
K 

X 
K 

X 
T 

X 
t 

Diaðt; T;KÞ 

Steps follow in the present study be summarize in Fig. 1. 

3. Results 

Demographic information of the individual include in this 
study be summarize in Table 1. Of the 273 individuals, 43 (15.75%) 
be diagnose with probable Alzheimer’s disease after the 24- 
month follow-up and be categorize a pMCI. 

Voxel-wise logistic regression analysis result in a scale odds 
ratio map with the high value in the orbitofrontal cortex, mid 
frontal cortex, mid temporal cortex, temporal occipital junction, 
posterior cingulate cortex, angular gyrus, precuneus, putamen, and 



Fig. 2. Regions with the high odds ratio values. (1) mid frontal cortex, (2) angular gyrus, (3) posterior cingulate cortex, (4) orbitofrontal cortex, (5) precuneus, (6) temporal 
occipital junction, (7) mid temporal cortex, (8) Putamen, and (9) nucleus accumbens be indicated. 

S. Mathotaarachchi et al. / Neurobiology of Aging xxx (2017) 1e11 5 
the nucleus accumbens (Fig. 2). The SUVR value from bilateral 
brain region be extract a described above and subsequently 
average to be use a regional SUVRs. These regional SUVR value 
be then use a feature on the predictor together with age, 
gender, and APOE4 gene status. 

Predictive performance from the 5 predictor be show in 
Table 2. The RUSRF predictor have the high predictive perfor- 
mance for both sMCI and pMCI individual base on the average 
area under the receiver operating characteristic curve (AUC) (0.906 
[�0.009]) and F1 score (0.583 [�0.044]). The RUSRF AUC score be 
significantly different from both the SVM and L2 logistic regression 
at p < 0.0025 and from random forest at p < 0.0125. Furthermore, 
the RUSRF F1 score be significantly different from SVM at p< 0.0025 
and from L2 logistic regression at p < 0.0125. The sensitivity of the 
RUSRF predictor only differ from the SVM predictor at p < 0.025. 
The RUSRF specificity be different from L2 logistic regression at p 
< 0.0125 and from SVM, L1 logistic regression, and random forest at 
p < 0.025. The p value threshold use here for statistical signifi- 
cance be Bonferroni adjust for multiple comparisons. 

According to McNemar’s c2 test (Table 2), only the RUSRF pre- 
dictor show a statistically significant difference with the random 
predictor at p < 0.01. Both regularize logistic regression predictor 
be significantly different at p < 0.1. However, the random forest 
predictor and the SVM predictor be not significantly different 
from the random predictor. The c2 statistic for the SVM predictor 
cannot be calculate a the output from the prediction from both 
SVM and the random predictor be identical. The SVM prediction 
for each test case, which be calculate a the mean of the pre- 
diction from all 10 iteration be 0. This result in an exaggerated 
accuracy of 84.15% (all true 0 case correctly predictedespecificity 
of 100%). 

Fig. 3A show the receiver operating characteristic (ROC) curve 
for the 4 predictor with their respective AUC values. The ROC curve 
for the novel RUSRF predictor dominate the other curve with an 
area of 0.91, follow by the L1 logistic predictor, random forest 
predictor, and the L2 logistic predictor. The AUC <0.5 for the SVM 
predictor (Table 2) indicate that the SVM predictor be a predictor 
for the sMCI class but not for the pMCI class. 

The relative feature importance from the novel RUSRF predictor 
be show in Fig. 3B. The most important feature indicate the brain 
region with the high contribution to predict the pMCI class. Ab 
accumulation measure by [18F]Florbetapir PET SUVR in the tem- 
poral occipital junction, mid temporal cortex, mid frontal cortex, 
and precuneus be the most important feature follow by the 
accumulation in other brain region and age, gender, and APOE4 
gene status. The feature importance from the random forest clas- 
sifier indicate the same 4 region to be the most important fea- 
tures (Supplementary Table 1). 

4. Discussion 

We have present a novel algorithm for predict the pro- 
gression from MCI to Alzheimer’s disease dementia use baseline 
amyloid PET measurements. The novel RUSRF algorithm us the 
random forest classifier a it base classifier along with advanced 
data sample technique to overcome inherent problem of the 
data sample to improve the prediction accuracy. This algorithmwas 
show to provide advantage a demonstrate by high AUC and 
F1 score when compare with the other widely-used prediction 
algorithm such a SVM, regularize logistic regression, and 
random forest. Furthermore, our preliminary data suggested, that 
this algorithm could perform comparably to themethods employ 
use MRI, FDG PET, CSF biomarkers, and their combination 
(Table 3). It be important to emphasize that the evaluation of the 
prediction algorithms, employ a completely independent test 
sample which be never use in training or feature selection steps. 
This method of evaluation resembles the expect outcome in an 
application (clinical and research) environment, which can be 
consider encourage to be use for the early diagnosis of Alz- 
heimer’s disease. 

Using the RUSRF algorithm, we obtain AUC and F1 score of 
0.906 (0.009) and 0.583 (0.044), respectively, for the independent 
test set. Generally, the progression to Alzheimer’s disease de- 
mentia of an MCI population within 24 month lie around 16.2% 
(Mitchell and Shiri-Feshki, 2009). Thus, in a prediction study, the 
pMCI class (the subset of individual progress to Alzheimer’s 
disease) be expect to lie close to the same proportion, create 
imbalanced classes. If the method to overcome this challenge be 
not involved, the prediction algorithm will ignore the error in the 
minority class (Japkowicz and Stephen, 2002). This can result in 
exaggerated accuracies, a the predictor can be bias toward the 
majority class, but it can also result in low sensitivity for the 



Table 2 
Summary of the performance of the predictor used. The statistical significance be measure compare with the RUSRF predictor 

Predictor AUC Accuracy F1 score Sensitivity Specificity vs. random predictor McNemar’s c2 p 

SVM 0.436 (0.24)*** 0.834 (0.023) 0.091 (0.193)*** 0.1 (0.212)* 0.972 (0.061)* NA 
L1 logistic 0.874 (0.047) 0.752 (0.043) 0.523 (0.051) 0.846 (0.051) 0.735 (0.046)* 8.1990e�02* 

L2 logistic 0.871 (0.007)*** 0.751 (0.02) 0.522 (0.023)** 0.854 (0.024) 0.732 (0.023)** 6.7250e�02* 

Random forest 0.872 (0.03)** 0.89 (0.014) 0.514 (0.076) 0.369 (0.071) 0.988 (0.009)* 3.7110e�01 

RUSRF 0.906 (0.009) 0.84 (0.012) 0.583 (0.044) 0.708 (0.079) 0.865 (0.007) 3.8670e�04*** 

Across these methods, RUSRF have the best AUC and F1 score. 
Key: AUC, area under the curve; MMSE, mini-mental state examination; pMCI, progressive MCI; RUSRF, RUS random forest; SVM, support vector machine. 
*p < 0.025, **p < 0.0125, and ***p < 0.0025. 

S. Mathotaarachchi et al. / Neurobiology of Aging xxx (2017) 1e116 
minority class. In the present study, pMCI individual be only 
15.75% of the sample. Therefore, compare the prediction accuracy 
base on the overall accuracy will lead to incorrect conclusion due 
to the adverse bias toward themajority class (sMCI). In other words, 
a classifier predict sMCI, regardless of the input features, will 
result in 84.25% overall accuracy a there will only be 15.75% 
incorrect prediction (pMCI individual predict a sMCI; 0% ac- 
curacy in pMCI class). To this regard, we have exclude the overall 
accuracy a a measure to compare predictor use in this study; 
however, we usedMcNemar’s c2 test to compare the sensitivity and 
the specificity. It be important to mention that most of the study 
conduct to predict the progression of Alzheimer’s disease de- 
mentia from MCI have not consider whether their sample 
represent the imbalanced proportion of the population (see 
Table 3). This can lead to inconsistent result when the study be 
use in a clinical set a the model have be train and test 
on a heighten representation of the pMCI population. Given that 
the population use in the present study be a closer representation 
of the MCI population, the result of the study can be consider 
transferable to the clinical use in early diagnosis. 

McNemar’s c2 test be use to evaluate the statistical significant 
difference between each predictor use in the study (RUSRF, SVM, 
regularize logistic regression, and random forest) against a 
random predictor. The random predictor be create by training 
each of the algorithm (RUSRF, SVM, regularize logistic regression, 
and random forest) with a randomly permute set of feature 
derive from the original training set. By do this, the relationship 
between the feature and the class be completely disrupt and 
the predictor be train to learn a random pattern. A statistically 
significant difference from a random predictor be only observe in 
the RUSRF predictor at p < 0.01, indicate that the novel algorithm 
be able to learn the classification pattern with a significant dif- 
ference to a randomly train classifier. Both regularize logistic 
regression algorithm show difference at p < 0.1, indicate a 
trend. This may be due to the limited number of sample use in the 
test set and the skewed proportion of sMCI and pMCI in- 
dividuals. However, neither the random forest predictor nor the 
SVM predictor show a significant difference from a random 
predictor, indicate their failure to learn the prediction relation- 
ship from the training set. 

McNemar’s c2 test and pair t-test be use to compare the 
performance of the RUSRF algorithm with other prediction algo- 
rithms. The AUC score can be consider a single metric for classifier 
performance when deal with highly unequal sample size 
(Eskildsen et al., 2013). The RUSRF algorithm achieve the high 
AUC score and be significantly different to both SVM and L2 logistic 
regression at p < 0.0025 and to random forest at p < 0.0125. 
Although the AUC of RUSRFwas nominally high than the AUC of L1 
logistic regression, it be not significantly different. However, the 
standard deviation of the AUC in L1 logistic regression be consid- 
erably great than that of RUSRF. This indicates that the perfor- 
mance of the L1 logistic regression be more sensitive to the noise 
present in the input feature (Frome et al., 2007; Fu et al., 2006), 
which can lead to inconsistent result in a clinical set when use 
in early diagnosis. We also use the F1 score to compare the pre- 
dictor performance a it considers both the precision and recall to 
construct the metric. The RUSRF predictor achieve the high F1 
score and be significantly different from SVM at p < 0.0025 and 
from L2 logistic regression at p < 0.0125. The F1 score of RUSRF be 
nominally high compare with both L1 logistic regression and 
random forest but be not significant. However, in the case of 
random forest, this can be due to the high precision result from a 
high specificity evenwith a low sensitivity value. It be important to 
mention that the F1 score can be influence by skewed class pro- 
portion (Jeni et al., 2013) and need to be consideredwhen use a a 
performancemeasure. Both AUC and F1 score be compare use 
pair t-tests with Bonferroni adjust threshold for inference. 

Comparing the sensitivity and specificity between RUSRF and 
the other predictor be perform use the McNemar’s c2 test. 
The sensitivity of the RUSRF predictor be significantly high only 
when compare to the SVM predictor. This can be greatly due to the 
low number of pMCI individual (n ¼ 13) in the test set, a the 
statistic be calculate consider only the pMCI individuals. 
Furthermore, both L1 and L2 logistic regression predictor be 
nominally high than the sensitivity of RUSRF. However, give the 
number of pMCI individuals, misclassification of even a single in- 
dividual can cause the sensitivity metric to fluctuate substantially. 
Although the specificity of both the SVM and the random forest 
predictor be high than RUSRF, their sensitivity be not 
acceptable for any clinical or research use. Among the RUSRF and 
logistic regression predictors, RUSRF achieve the high speci- 
ficity and be significantly different from L2 logistic regression at p 
< 0.0125 and from L1 logistic regression at p < 0.025. Although the 
SVM classifier be use widely in many applications, our analysis 
indicate that, at it current configurationwith a radial basis kernel, 
it produce a very low sensitivity and be not suitable in identify 
pMCI individuals. However, the SVM classifier can be train with a 
number of kernel function such a the polynomial kernel func- 
tions, sigmoid kernel functions, and linear kernel functions, and this 
would lead to increase sensitivity and overall classification 
performance. 

Direct comparison with other similar study conduct to 
ass the predictive capability of amyloid imagingebased bio- 
marker cannot be perform due to a number of reason (see 
summarize comparison in Table 3). Most study (Brück et al., 
2013; Hatashita and Yamasaki, 2013; Jack et al., 2010a,b; Wolk 
et al., 2009) have use [11C]PiB PET a the image biomarker, a 
it be commonly use before the introduction of [18F]-based radio 
ligand (except the author of (Waragai et al., 2009), have use [11C] 
BF-227 PET). Both Teipel et al. (2015) and Schreiber et al. (2015) 
have use [18F]Florbetapir PET; however, Teipel et al. (2015) have 
use both [18F]FDG PET and MRI biomarkers in combination with 
amyloid PET a the input feature for the predictor. Furthermore, 
study with similar observation period (Brück et al., 2013; Ewers 
et al., 2012; Jack et al., 2010a,b; Waragai et al., 2009) have re- 
port much high progression rates. These increase rate may 



Fig. 3. (A) ROC curve for the 4 predictor with correspond AUC values. The ROC curve be plot for the median perform predictor from the cross-validation steps. The 
high AUC be record with the curve for RUSRF. (B) Relative feature importance from the RUSRF predictor. The temporal occipital junction, the mid temporal cortex, the mid 
frontal cortex, and the precuneus show the high importance for the prediction. Abbreviations: AUC, area under the curve; ROC, receiver operating characteristic; RUSRF, RUS 
random forest. 

S. Mathotaarachchi et al. / Neurobiology of Aging xxx (2017) 1e11 7 



Table 3 
Summary of several previous study perform to predict progression to Alzheimer’s disease dementia from MCI 

Study Data Validation Result (ACCeAccuracy, SENeSensitivity, 
SPEeSpecificity) 

Waragai et al., 2009 Total: 13, sMCI: 7, pMCI: 6 
Follow-up: 27 mo 
[11C]BF-227 PET 

No validation SEN: 100%, SPE: 71% 

Hatashita and Yamasaki, 2013 Total: 68, sMCI: 38, pMCI: 30 
Follow-up: 19.2 mo 
[11C]PIB PET 

No validation SEN: 97%, SPE: 42% 

Brück et al., 2013 Total: 29, sMCI: 12, pMCI: 17 
Follow-up: 24 mo 
[11C]PIB PET and [18F]FDG PET 

No validation SEN: 88%, SPE: 71% 

Wolk et al., 2009 Total: 26, sMCI: 21, pMCI: 5 
Follow-up: 21.2 mo 
[11C]PIB PET 

No validation SEN: 100%, SPE: 55% 

Ewers et al., 2012 Total: 131, sMCI: 56, pMCI:75 
Follow-up: 24 mo 
[11C]PIB PET 

No validation SEN: 81%, SPE: 83% 

Jack et al., 2010a,b Total: 218, sMCI: 125, pMCI: 93 
Follow-up: 24 mo 
[11C]PIB PET 

No validation SEN: 50%, SPE: 81% 

Schreiber et al., 2015 Total: 401, sMCI: 340, pMCI: 61 
Follow-up: 19.2 mo 
[18F]Florbetapir PET 

No validation SEN: 87%, SPE: 50% 

Teipel et al., 2015 Total: 127, sMCI: 88, pMCI: 39 
Follow-up: 17.3 mo 
[18F]Florbetapir PET, [18F]FDG PET and MRI 

Cross validation ACC: 72% 
SEN: 30%, SPE: 90% 
AUC: 0.70 

Moradi et al., 2015 Total: 264, sMCI: 100, pMCI: 164 
Follow-up: 0e36 mo 
MRI and cognition 

Cross validation ACC: 82% 
SEN: 87%, SPE: 74% 
AUC: 0.90 

Misra et al., 2009 Total: 103, sMCI: 76, pMCI: 27 
Follow-up: 0e36 mo 
MRI 

Cross validation ACC: 75%e80% 
AUC: 0.77 

Davatzikos et al., 2011 Total: 239, sMCI: 170, pMCI: 69 
Follow-up: 0e36 mo 
MRI and CSF 

Cross validation ACC: 62% 
AUC: 0.73 

Ye et al., 2012 Total: 319, sMCI: 177, pMCI: 142 
MRI, genetic and cognitive measure 

Cross validation AUC: 0.86 

Zhang and Shen, 2012 Total: 88, sMCI: 50, pMCI: 38 
Follow-up: 0e24 mo 
MRI, [18F]FDG PET and CSF 

Cross validation ACC: 78% 
SEN: 79%, SPE: 78% 
AUC: 0.77 

Gaser et al., 2013 Total: 195, sMCI: 62, pMCI: 133 
Follow-up: 0e36 mo 
MRI 

Independent test set AUC: 0.78 

Cuingnet et al., 2011 Total: 210, sMCI: 134, pMCI: 76 
Follow-up: 0e18 mo 
MRI 

Independent test set ACC: 67% 
SEN: 62%, SPE: 69% 

Eskildsen et al., 2013 Total: 388, sMCI: 227, pMCI: 161 
Follow-up: 0e48 mo 
MRI 

Cross validation AUC: 0.71a 

Wolz et al., 2011 Total: 405, sMCI: 238, pMCI: 167 
Follow-up: 0-48 moth 
MRI 

Cross validation ACC: 68% 
SEN: 67%, SPE: 69% 

Chupin et al., 2009 Total: 210, sMCI: 134, pMCI: 76 
Follow-up: 0e18 mo 
MRI 

Independent test set ACC: 64% 
SEN: 60%, SPE: 65% 

Cho et al., 2012 Total: 203, sMCI: 131, pMCI: 72 
Follow-up: 0e18 mo 
MRI 

Independent test set ACC: 71% 
SEN: 63%, SPE: 76% 

Coupé et al., 2012 Total: 405, sMCI: 238, pMCI: 167 
Follow-up: 0e48 mo 
MRI 

Cross validation ACC: 74% 
SEN: 73%, SPE: 74% 

Westman et al., 2012 Total: 318, sMCI: 256, pMCI: 62 
Follow-up: 0e12 mo 
MRI 

Cross validation ACC: 59% 
SEN: 74%, SPE: 56% 

Querbes et al., 2009 Total: 122, sMCI: 50, pMCI: 72 
Follow-up: 0e24 mo 
MRI 

Cross validation ACC: 73% 
SEN: 75%, SPE: 69% 

Koikkalainen et al., 2011 Total: 369, sMCI: 215, pMCI: 154 
Follow-up (mean): 18.1 mo 
MRI 

Cross validation ACC: 72% 
SEN: 77%, SPE: 71% 

Retico et al., 2015 Total: 302, sMCI: 166, pMCI: 136 
Follow-up: 0e24 mo 
MRI 

Independent test set ACC: 66% 
SEN: 70%, SPE: 62% 
AUC: 0.71 

S. Mathotaarachchi et al. / Neurobiology of Aging xxx (2017) 1e118 



Table 3 (continued ) 

Study Data Validation Result (ACCeAccuracy, SENeSensitivity, 
SPEeSpecificity) 

Doyle et al., 2014 Total: 226, sMCI: 164, pMCI: 62 
Follow-up: 0e12 mo 
MRI 

Independent test set (different cohort) ACC: 82% 
SEN: 81%, SPE: 72% 
AUC: 0.81 

Lebedev et al., 2014 Total: 139, sMCI: 16, pMCI: 123 
Follow-up: 0e24 mo 
MRI 

Independent test set ACC: 82% 
SEN: 83%, SPE: 81% 
AUC: 0.83 

This study Total: 263, sMCI: 230, pMCI: 43 
Follow-up: 24 mo 
[18F]Florbetapir PET 

Independent test set ACC: 84% 
SEN: 71%, SPE: 87% 
AUC: 0.91 

Key: CSF, cerebrospinal fluid; MRI, magnetic resonance imaging; pMCI, progressive MCI; sMCI, stable MCI. 
a Follow-up period match to present study. 

S. Mathotaarachchi et al. / Neurobiology of Aging xxx (2017) 1e11 9 
be due to the lownumber of subject include (Waragai et al., 2009) 
by specialized memory clinic (Brück et al., 2013) and the low 
baseline Mini-Mental State Examination score report 
(Brück et al., 2013; Ewers et al., 2012; Jack et al., 2010a,b; Waragai 
et al., 2009). 

Nevertheless, these study except for Teipel et al. (2015) have 
not use any model evaluation technique, such a cross validation, 
to ass how their model will generalize to an independent data 
set, which be of paramount importance to be successfully use a an 
early diagnosis tool in a clinical environment. We obtain a high 
overall accuracy, AUC, and sensitivity compare with the accuracy 
report by Teipel et al. (2015). The low sensitivity value report 
in Teipel et al. (2015) may be due the low proportion of pMCI 
individual include in the study, lead to a bias toward the 
majority sMCI group. The novel algorithm introduce in this study 
compensates for this “imbalanced class problem” by use data 
sample technique a mention earlier. 

Compared with several previous study use not only Ab 
PETebased biomarkers, the algorithm introduce here seem 
promising with a record average AUC of 0.906 for an independent 
test set (accuracy: 0.84; sensitivity: 0.708; and specificity: 0.865). 
Often, study use performance measure (AUC, accuracy, sensi- 
tivity, and specificity) base only on cross validation; however, this 
make the prediction model bias toward the data set use a all 
the sample be use for training at some point in the analysis. The 
present study us a completely independent test set to evaluate 
the true generalization capability of the model presented. The in- 
dependent test set be not use in the feature extraction step or 
the model training steps. By evaluate the performance of the 
prediction model base on a completely independent test set, 
we can retrieve the true expect performance of the model when 
use in a clinical environment a an early diagnostic tool. The 
generalization capability can be further improve by training the 
model on data acquire from multiple cohorts, a use a test set 
from the same cohort can add bias to the prediction model. 

The most important characteristic of the present study be it 
ability to overcome the inherent imbalance of proportion between 
pMCI and sMCI individual and perform comparably or even 
good than the previous studies. Studies conduct by Cho et al. 
(2012), Davatzikos et al. (2011), Misra et al. (2009) and Teipel 
et al. (2015) use cohort with imbalanced proportion similar to 
the present study to train their predictionmodels, which result in 
low sensitivity score and low AUC values. 

Another important outcome from the present study be the 
relative predictive capability of the investigate brain region 
(Fig. 3B) base on Ab retention. Our study indicate that the 4 brain 
regions, the temporal occipital junction, mid temporal cortex, mid 
frontal cortex and precuneus to have the high predictive ability. 
Other study conduct with Ab PETebased biomarkers also 
identify similar region to have the high difference between 
individual progress to Alzheimer’s disease and sMCI individual 
(Brück et al., 2013; Koivunen et al., 2011; Teipel et al., 2015). These 
region be know to show Ab deposition in relatively late stage 
of the course of Alzheimer’s disease. This agrees with the idea that 
the region with early deposition of Ab such a the posterior 
cingulate cortex, already reach a plateau in the MCI stage, add 
little information to discriminate individual progress to Alz- 
heimer’s disease, whereas region with late build-up be more 
relevant in discriminate stable and progress MCI individuals. 
Interestingly, the feature selection technique identify subcortical 
structure such a the putamen and the nucleus accumbens to be 
use a feature for classification. It be worth to emphasize that 
patient with AD have show increase deposition of Ab in these 
subcortical brain region occur late in the disease spectrum 
(Ishibashi et al., 2014). Furthermore, these region receive pro- 
jections from different prefrontal sub-regions, mainly from the 
medial prefrontal cortex (Ferry et al., 2000; Ongür and Price, 2000), 
and their association with behavioral characteristic and cognitive 
performance be well know (de Jong et al., 2012; Diekhof et al., 
2012). When evaluate the brain Ab deposition, the consensus of 
the field of Alzheimer’s disease be to use the average deposition 
from the brain region characteristic of Alzheimer’s disease. How- 
ever, this method average the Ab deposition in brain region which 
accumulate in different stage of Alzheimer’s disease, and will 
result in a suboptimal discriminate capability compare with the 
method introduce in the article (see Supplementary Material for 
result of RUSRF performance with average brain Ab deposition). 
Identifying the relative importance of Ab deposition in various 
brain region provide many benefit to research study of anti- 
amyloid agent to evaluate the treatment’s effect in prevent or 
slow the progression to Alzheimer’s disease. 

It be important to mention several limitation of the present 
study. Any Alzheimer’s disease study involve in vivo data suffers 
from the inherent uncertainty of the diagnosis (Eskildsen et al., 
2013). This be because the diagnosis of Alzheimer’s disease can 
only be confirm with autopsy data. Therefore, any clinical diag- 
nosis will always be “probable Alzheimer’s disease.” It be estimate 
that around 10% of this “probable Alzheimer’s disease” diagnosis 
can be mislabeled “Lewy Body disease” or “Frontotemporal de- 
mentia” (Ranginwala et al., 2008). Thus, the pattern learnt by the 
predictor might not be specific to Alzheimer’s disease; however, 
this have be partially address by use an Alzheimer’s dis- 
easeespecific biomarker such a Ab PET compare with a general 
neurodegenerative biomarker such a MRI or glucose metabolism. 

It be important to emphasize that the population include in this 
analysis represent a select group of amnestic MCI individual 
motivate to participate in a dementia study, a such, for reason 
related to the study inclusion criterion these individual may not 
represent the general MCI population. Therefore, it would be highly 
desirable to replicate our finding in a population-based cohort. 



S. Mathotaarachchi et al. / Neurobiology of Aging xxx (2017) 1e1110 
Furthermore, the predictor present here be bias to the [18F] 
Florbetapir PET acquisition protocol follow by ADNI, a the 
training and test be do use only the data acquire from the 
ADNI database. Hence, clinical implementation of the present 
study will still require additional reliability assessment by training 
the predictor use multiple acquisition protocol to increase the 
robustness of the prediction. Similarly, the feature extraction step 
include identify brain region with a scale odds ratio above 
1.5, base on the expert opinion. The rationale behind this step be 
to select the anatomically significant brain region with an increase 
of odds for develop Alzheimer’s disease of 50% for each 1 stan- 
dard deviation increase of SUVR. However, this step can add bias 
toward the subjective opinion of the expert and can be avoid by 
select brain region base on the opinion of multiple expert or 
by use an automate clusterebased technique. Furthermore, due 
to the computational cost of perform multiple voxel-wise lo- 
gistic regression analyses, the feature selection technique employ 
a single voxel-wise logistic regression analysis include all the 
subject (excluding the one use a the final test dataset). How- 
ever, the stability of the identify region can be further increase 
by employ an undersampling technique in identify the 
features. 

In conclusion, we present a novel algorithm to predict the pro- 
gression to Alzheimer’s disease dementia within MCI individual 
base on their Ab PET measurements. The predictor present here 
achieve a high rate of accuracy with an AUC of 0.906 for an in- 
dependent test set. The novel algorithm overcomes the inherent 
imbalance of proportion between stable and pMCI see in a pop- 
ulation of MCI individuals, make it ideally suit for a clinical 
environment a an early diagnostic tool. Demonstration of such a 
tool use the data present in the current article can be found at 
http://predictalz.tnlmcgill.ca/PredictAlz_Amy. 

Disclosure statement 

The author have no actual or potential conflict of interest. 

Acknowledgements 

Data collection and share for this project be fund by the 
ADNI (National Institutes of Health Grant U01 AG024904) and DOD 
ADNI (Department of Defense award number W81XWH-12-2- 
0012). ADNI be fund by the National Institute on Aging, the Na- 
tional Institute of Biomedical Imaging and Bioengineering, and 
through generous contribution from the following: AbbVie, Alz- 
heimer’s Association; Alzheimer’s Drug Discovery Foundation; 
Araclon Biotech; BioClinica, Inc; Biogen; Bristol-Myers Squibb 
Company; CereSpir, Inc; Eisai Inc; Elan Pharmaceuticals, Inc; Eli Lilly 
and Company; EuroImmun; F. Hoffmann-La Roche Ltd and it 
affiliate company Genentech, Inc; Fujirebio; GE Healthcare; IXICO 
Ltd; Janssen Alzheimer Immunotherapy Research & Development, 
LLC; Johnson & Johnson Pharmaceutical Research & Development 
LLC; Lumosity; Lundbeck; Merck & Co, Inc; Meso Scale Diagnostics, 
LLC; NeuroRx Research; Neurotrack Technologies; Novartis Phar- 
maceuticals Corporation; Pfizer Inc; Piramal Imaging; Servier; 
Takeda Pharmaceutical Company; and Transition Therapeutics. The 
Canadian Institutes of Health Research also provide fund to sup- 
port ADNI clinical site in Canada. Private sector contribution be 
facilitate by the Foundation for the National Institutes of Health 
(www.fnih.org). The grantee organization be the Northern California 
Institute for Research and Education, and the study be coordinate 
by the Alzheimer’s Disease Cooperative Study at the University of 
California, San Diego. ADNI data be disseminate by the Labo- 
ratory for Neuro Imaging at the University of Southern California. 
This work be support by the Canadian Institutes of Health 
Research (CIHR) [MOP-11-51-31], Canadian Consortium of Neuro- 
degeneration and Aging, the Alan Tiffin Foundation, the Alzheimer’s 
Association [NIRG-12-92090, NIRP-12-259245], the Fonds de 
Recherche du QuébeceSanté (P-RN), and the Centre for Studies on 
Prevention of Alzheimer’s Disease (StoP-AD Centre). 
Appendix A. Supplementary data 

Supplementary data associate with this article can be found, in 
the online version, at http://dx.doi.org/10.1016/j.neurobiolaging. 
2017.06.027. 
References 

Ad-Dab’bagh, Y., Einarson, D., Lyttelton, O., Muehlboeck, J.S., Mok, K., Ivanov, O., 
Vincent, R.D., Lepage, C., Lerch, J., Fombonne, E., Evans, A.C., 2006. The CIVET 
image-processing environment: a fully automate comprehensive pipeline for 
anatomical neuroimaging research. In: Corbetta, M. (Ed.), Proceedings of the 
12th Annual Meeting of the Human Brain Mapping Organization. Neuroimage, 
Florence, Italy. 

Apostolova, L.G., Hwang, K.S., Kohannim, O., Avila, D., Elashoff, D., Jack, C.R., Shaw, L., 
Trojanowski, J.Q., Weiner, M.W., Thompson, P.M., 2014. ApoE4 effect on auto- 
mat diagnostic classifier for mild cognitive impairment and Alzheimer’s 
disease. Neuroimage Clin. 4, 461e472. 

Braak, H., Braak, E., 1991. Neuropathological stage of Alzheimer-related changes. 
Acta Neuropathol. 82, 239e259. 

Breiman, L., 2001. Random forests. Mach. Learn 45, 5e32. 
Brück, A., Virta, J.R., Koivunen, J., Koikkalainen, J., Scheinin, N.M., Helenius, H., 

Någren, K., Helin, S., Parkkola, R., Viitanen, M., Rinne, J.O., 2013. [11C]PIB, [18F] 
FDG and MR image in patient with mild cognitive impairment. Eur. J. Nucl. 
Med. Mol. Imaging 40, 1567e1572. 

Buerger, K., Ewers, M., Pirttilä, T., Zinkowski, R., Alafuzoff, I., Teipel, S.J., 
DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H., Hampel, H., 2006. CSF 
phosphorylated tau protein correlate with neocortical neurofibrillary pathol- 
ogy in Alzheimer’s disease. Brain 129, 3035e3041. 

Cho, Y., Seong, J.-K., Jeong, Y., Shin, S.Y., 2012. Individual subject classification for 
Alzheimer’s disease base on incremental learn use a spatial frequency 
representation of cortical thickness data. Neuroimage 59, 2217e2230. 

Chupin, M., Gérardin, E., Cuingnet, R., Boutet, C., Lemieux, L., Lehéricy, S., Benali, H., 
Garnero, L., Colliot, O., 2009. Fully automatic hippocampus segmentation and 
classification in Alzheimer’s disease and mild cognitive impairment apply on 
data from ADNI. Hippocampus 19, 579e587. 

Collins, D.L., Evans, A.C., 1997. Animal: validation and application of nonlinear 
registration-based segmentation. Int. J. Pattern Recognit. Artif. Intell. 11, 
1271e1294. 

Collins, D.L., Holmes, C.J., Peters, T.M., Evans, A.C., 1995. Automatic 3-D model-based 
neuroanatomical segmentation. Hum. Brain Mapp. 3, 190e208. 

Coupé, P., Eskildsen, S.F., Manjón, J.V., Fonov, V.S., Collins, D.L., 2012. Simultaneous 
segmentation and grade of anatomical structure for patient’s classification: 
application to Alzheimer’s disease. Neuroimage 59, 3736e3747. 

Cuingnet, R., Gerardin, E., Tessieras, J., Auzias, G., Lehéricy, S., Habert, M.-O., 
Chupin, M., Benali, H., Colliot, O., 2011. Automatic classification of patient with 
Alzheimer’s disease from structural MRI: a comparison of ten method use 
the ADNI database. Neuroimage 56, 766e781. 

Davatzikos, C., Bhatt, P., Shaw, L.M., Batmanghelich, K.N., Trojanowski, J.Q., 2011. 
Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern 
classification. Neurobiol. Aging 32, 2322.e19e2322.e27. 

de Jong, L.W., Wang, Y., White, L.R., Yu, B., van Buchem, M.A., Launer, L.J., 2012. 
Ventral striatal volume be associate with cognitive decline in old people: a 
population base MR-study. Neurobiol. Aging 33, 424.e1e424.e10. 

Diekhof, E.K., Kaps, L., Falkai, P., Gruber, O., 2012. The role of the human ventral 
striatum and the medial orbitofrontal cortex in the representation of reward 
magnitude? An activation likelihood estimation meta-analysis of neuroimaging 
study of passive reward expectancy and outcome processing. Neuro- 
psychologia 50, 1252e1266. 

Doyle, O.M., Westman, E., Marquand, A.F., Mecocci, P., Vellas, B., Tsolaki, M., 
K1oszewska, I., Soininen, H., Lovestone, S., Williams, S.C.R., Simmons, A., 2014. 
Predicting progression of Alzheimer’s disease use ordinal regression. PLoS 
One 9, e105542. 

Eskildsen, S.F., Coupé, P., García-Lorenzo, D., Fonov, V., Pruessner, J.C., Collins, D.L., 
2013. Prediction of Alzheimer’s disease in subject with mild cognitive 
impairment from the ADNI cohort use pattern of cortical thinning. Neuro- 
image 65, 511e521. 

Ewers, M., Insel, P., Jagust, W.J., Shaw, L., Trojanowski, J.Q., Aisen, P., Petersen, R.C., 
Schuff, N., Weiner, M.W., 2012. CSF biomarker and PIB-PET-derived beta-amy- 
loid signature predicts metabolic, gray matter, and cognitive change in non- 
demented subjects. Cereb. Cortex 22, 1993e2004. 

Fagan, A.M., Mintun, M.A., Mach, R.H., Lee, S.-Y., Dence, C.S., Shah, A.R., LaRossa, G.N., 
Spinner, M.L., Klunk, W.E., Mathis, C.A., DeKosky, S.T., Morris, J.C., 

http://predictalz.tnlmcgill.ca/PredictAlz_Amy 
http://www.fnih.org 
http://dx.doi.org/10.1016/j.neurobiolaging.2017.06.027 
http://dx.doi.org/10.1016/j.neurobiolaging.2017.06.027 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref1 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref1 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref1 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref1 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref1 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref1 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref2 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref2 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref2 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref2 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref2 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref3 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref3 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref3 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref4 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref4 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref5 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref5 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref5 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref5 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref5 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref6 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref6 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref6 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref6 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref6 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref7 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref7 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref7 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref7 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref8 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref8 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref8 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref8 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref8 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref9 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref9 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref9 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref9 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref10 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref10 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref10 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref11 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref11 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref11 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref11 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref12 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref12 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref12 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref12 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref12 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref13 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref13 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref13 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref13 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref14 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref14 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref14 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref14 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref15 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref15 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref15 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref15 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref15 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref15 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref16 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref16 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref16 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref16 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref16 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref17 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref17 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref17 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref17 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref17 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref18 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref18 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref18 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref18 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref18 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref19 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref19 


S. Mathotaarachchi et al. / Neurobiology of Aging xxx (2017) 1e11 11 
Holtzman, D.M., 2006. Inverse relation between in vivo amyloid image load 
and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 59, 512e519. 

Ferry, A.T., Ongür, D., An, X., Price, J.L., 2000. Prefrontal cortical projection to the 
striatum in macaque monkeys: evidence for an organization related to pre- 
frontal networks. J. Comp. Neurol. 425, 447e470. 

Fonov, V., Evans, A., McKinstry, R., Almli, C., Collins, D., 2009. Unbiased nonlinear 
average age-appropriate brain template from birth to adulthood. Neuroimage 
47, S102. 

Frome A., Sha F., Singer Y., Malik J., Sha F., Malik J., Learning globally-consistent local 
distance function for shape-based image retrieval and classification, In: Com- 
puter Vision, 2007. ICCV 2007. IEEE 11th International Conference on IEEE, pp. 
1e8. http://dx.doi.org/10.1109/ICCV.2007.4408839. 

Fu, H., Ng, M.K., Nikolova, M., Barlow, J.L., 2006. Efficient minimization method of 
mixed l2-l1 and l1-l1 norm for image restoration. SIAM J. Sci. Comput. 27, 
1881e1902. 

Gaser, C., Franke, K., Klöppel, S., Koutsouleris, N., Sauer, H., 2013. BrainAGE in mild 
cognitive impaired patients: predict the conversion to Alzheimer’s disease. 
PLoS One 8, e67346. 

Gelosa, G., Brooks, D., 2012. The prognostic value of amyloid imaging. Eur. J. Nucl. 
Med. Mol. Imaging 39, 1207e1219. 

Hall, A., Mattila, J., Koikkalainen, J., Lötjonen, J., Wolz, R., Scheltens, P., Frisoni, G., 
Tsolaki, M., Nobili, F., Freund-levi, Y., Minthon, L., Frölich, L., Hampel, H., 
Visser, P.J., Soininen, H., 2015. Predicting progression from cognitive impairment 
to Alzheimer’s disease with the Disease State Index. Curr. Alzheimer Res. 12, 
69e79. 

Hatashita, S., Yamasaki, H., 2013. Diagnosed mild cognitive impairment due to 
Alzheimer’s disease with PET biomarkers of beta amyloid and neuronal 
dysfunction. PLoS One 8, e66877. 

Holland, D., McEvoy, L.K., Desikan, R.S., Dale, A.M., 2012. Enrichment and 
stratification for predementia Alzheimer disease clinical trials. PLoS One 7, 
e47739. 

Huttunen, H., Manninen, T., Kauppi, J.-P., Tohka, J., 2012. Mind reading with regu- 
larized multinomial logistic regression. Mach. Vis. Appl. 24, 1311e1325. 

Ishibashi, K., Ishiwata, K., Toyohara, J., Murayama, S., Ishii, K., 2014. Regional analysis 
of striatal and cortical amyloid deposition in patient with Alzheimer’s disease. 
Eur. J. Neurosci. 40, 2701e2706. 

Jack, C.R., Knopman, D.S., Jagust, W.J., Petersen, R.C., Weiner, M.W., Aisen, P.S., 
Shaw, L.M., Vemuri, P., Wiste, H.J., Weigand, S.D., Lesnick, T.G., Pankratz, V.S., 
Donohue, M.C., Trojanowski, J.Q., 2013. Tracking pathophysiological process in 
Alzheimer’s disease: an update hypothetical model of dynamic biomarkers. 
Lancet Neurol. 12, 207e216. 

Jack, C.R., Knopman, D.S., Jagust, W.J., Shaw, L.M., Aisen, P.S., Weiner, M.W., 
Petersen, R.C., Trojanowski, J.Q., 2010a. Hypothetical model of dynamic bio- 
marker of the Alzheimer’s pathological cascade. Lancet Neurol. 9, 119e128. 

Jack, C.R., Wiste, H.J., Vemuri, P., Weigand, S.D., Senjem, M.L., Zeng, G., 
Bernstein, M.A., Gunter, J.L., Pankratz, V.S., Aisen, P.S., Weiner, M.W., 
Petersen, R.C., Shaw, L.M., Trojanowski, J.Q., Knopman, D.S., 2010b. Brain beta- 
amyloid measure and magnetic resonance image atrophy both predict 
time-to-progression from mild cognitive impairment to Alzheimer’s disease. 
Brain 133, 3336e3348. 

Japkowicz, N., Stephen, S., 2002. The class imbalance problem: a systematic study. 
Intell. Data Anal. 6, 429e449. 

Jeni, L.A., Cohn, J.F., De La Torre, F., 2013. Facing imbalanced dataerecommendations 
for the use of performance metrics. 2013 Hum. Assoc. Conf. Affect. Comput. 
Intell. Interact 245e251. 

Koikkalainen, J., Lötjönen, J., Thurfjell, L., Rueckert, D., Waldemar, G., Soininen, H., 
2011. Multi-template tensor-based morphometry: application to analysis of 
Alzheimer’s disease. Neuroimage 56, 1134e1144. 

Koivunen, J., Scheinin, N., Virta, J.R., Aalto, S., Vahlberg, T., Nagren, K., 
Helin, S., Parkkola, R., Viitanen, M., Rinne, J.O., Någren, K., Helin, S., 
Parkkola, R., Viitanen, M., Rinne, J.O., 2011. Amyloid PET image in pa- 
tients with mild cognitive impairment: a 2-year follow-up study. 
Neurology 76, 1085e1090. 

Lebedev, A.V., Westman, E., Van Westen, G.J.P., Kramberger, M.G., Lundervold, A., 
Aarsland, D., Soininen, H., K1oszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., 
Lovestone, S., Simmons, A., 2014. Random Forest ensemble for detection and 
prediction of Alzheimer’s disease with a good between-cohort robustness. 
Neuroimage Clin. 6, 115e125. 

Markesbery, W.R., 2010. Neuropathologic alteration in mild cognitive impairment: 
a review. J. Alzheimer’s Dis. 19, 221e228. 

Mathotaarachchi, S., Wang, S., Shin, M., Pascoal, T.A., Benedet, A.L., Kang, M.S., 
Beaudry, T., Fonov, V.S., Gauthier, S., Labbe, A., Rosa-Neto, P., 2016. VoxelStats: a 
MATLAB package for multi-modal voxel-wise brain image analysis. Front. 
Neuroinform 10, 20. 

Mazziotta, J.C., Toga, A.W., Evans, A., Fox, P., Lancaster, J., 1995. A probabilistic atlas of 
the human brain: theory and rationale for it development. The International 
Consortium for Brain Mapping (ICBM). Neuroimage 2, 89e101. 

McEvoy, L.K., Brewer, J.B., 2010. Quantitative structural MRI for early detection of 
Alzheimer’s disease. Expert Rev. Neurother. 10, 1675e1688. 

Misra, C., Fan, Y., Davatzikos, C., 2009. Baseline and longitudinal pattern of brain 
atrophy in MCI patients, and their use in prediction of short-term conversion to 
AD: result from ADNI. Neuroimage 44, 1415e1422. 

Mitchell, A.J., Shiri-Feshki, M., 2009. Rate of progression of mild cognitive impair- 
ment to dementiaemeta-analysis of 41 robust inception cohort studies. Acta 
Psychiatr. Scand. 119, 252e265. 
Moradi, E., Pepe, A., Gaser, C., Huttunen, H., Tohka, J., 2015. Machine learn 
framework for early MRI-based Alzheimer’s conversion prediction in MCI sub- 
jects. Neuroimage 104, 398e412. 

Morris, J.C., Roe, C.M., Grant, E.A., Head, D., Storandt, M., Goate, A.M., Fagan, A.M., 
Holtzman, D.M., Mintun, M.A., 2009. Pittsburgh compound B image and 
prediction of progression from cognitive normality to symptomatic Alzheimer 
disease. Arch. Neurol. 66, 1469e1475. 

Mosconi, L., Brys, M., Glodzik-Sobanska, L., De Santi, S., Rusinek, H., de Leon, M.J., 
2007. Early detection of Alzheimer’s disease use neuroimaging. Exp. Gerontol. 
42, 129e138. 

Ongür, D., Price, J.L., 2000. The organization of network within the orbital and 
medial prefrontal cortex of rats, monkey and humans. Cereb. Cortex 10, 
206e219. 

Petersen, R.C. (Ed.), 2003. Mild Cognitive Impairment: Aging to Alzheimer’s Disease. 
Oxford University Press, Oxford. 

Pouryamout, L., Dams, J., Wasem, J., Dodel, R., Neumann, A., 2012. Economic eval- 
uation of treatment option in patient with Alzheimer’s disease: a systematic 
review of cost-effectiveness analyses. Drugs 72, 789e802. 

Querbes, O., Aubry, F., Pariente, J., Lotterie, J.-A., Démonet, J.-F., Duret, V., Puel, M., 
Berry, I., Fort, J.-C., Celsis, P., 2009. Early diagnosis of Alzheimer’s disease use 
cortical thickness: impact of cognitive reserve. Brain 132, 2036e2047. 

Ranginwala, N.A., Hynan, L.S., Weiner, M.F., White, C.L., 2008. Clinical criterion for the 
diagnosis of Alzheimer disease: still good after all these years. Am. J. Geriatr. 
Psychiatry 16, 384e388. 

Retico, A., Bosco, P., Cerello, P., Fiorina, E., Chincarini, A., Fantacci, M.E., 2015. Pre- 
dictive model base on support vector machines: whole-brain versus regional 
analysis of structural MRI in the Alzheimer’s disease. J. Neuroimaging 25, 
552e563. 

Robbins, S., Evans, A.C., Collins, D.L., Whitesides, S., 2004. Tuning and compare 
spatial normalization methods. Med. Image Anal. 8, 311e323. 

Schreiber, S., Landau, S.M., Fero, A., Schreiber, F., Jagust, W.J., 2015. Comparison of 
visual and quantitative Florbetapir F 18 positron emission tomography analysis 
in predict mild cognitive impairment outcomes. JAMA Neurol. 72, 
1183e1190. 

Seiffert, C., Khoshgoftaar, T.M., Van Hulse, J., Napolitano, A., 2008. RUSBoost: 
Improving classification performance when training data be skewed. In: 2008 
19th International Conference on Pattern Recognition. IEEE, pp. 1e4. 

Seiffert, C., Khoshgoftaar, T.M., Van Hulse, J., Napolitano, A., 2010. RUSBoost: a 
hybrid approach to alleviate class imbalance. IEEE Trans. Syst. Man. Cybern. 
Part A Syst. Humans 40, 185e197. 

Sled, J.G., Zijdenbos, A.P., Evans, A.C., 1998. A nonparametric method for automatic 
correction of intensity nonuniformity in MRI data. IEEE Trans. Med. Imaging 17, 
87e97. 

Smith, S.M., 2002. Fast robust automate brain extraction. Hum. Brain Mapp. 17, 
143e155. 

Teipel, S.J., Kurth, J., Krause, B., Grothe, M.J., 2015. The relative importance of im- 
age marker for the prediction of Alzheimer’s disease dementia in mild 
cognitive impairment - beyond classical regression. Neuroimage Clin. 8, 
583e593. 

Trzepacz, P.T., Yu, P., Sun, J., Schuh, K., Case, M., Witte, M.M., Hochstetler, H., Hake, A., 
2014. Comparison of neuroimaging modality for the prediction of conversion 
from mild cognitive impairment to Alzheimer’s dementia. Neurobiol. Aging 35, 
143e151. 

Waragai, M., Okamura, N., Furukawa, K., Tashiro, M., Furumoto, S., Funaki, Y., 
Kato, M., Iwata, R., Yanai, K., Kudo, Y., Arai, H., 2009. Comparison study of am- 
yloid PET and voxel-based morphometry analysis in mild cognitive impairment 
and Alzheimer’s disease. J. Neurol. Sci. 285, 100e108. 

Westman, E., Muehlboeck, J.-S., Simmons, A., 2012. Combining MRI and CSF mea- 
sures for classification of Alzheimer’s disease and prediction of mild cognitive 
impairment conversion. Neuroimage 62, 229e238. 

Wolk, D.A., Price, J.C., Saxton, J.A., Snitz, B.E., James, J.A., Lopez, O.L., Aizenstein, H.J., 
Cohen, A.D., Weissfeld, L.A., Mathis, C.A., Klunk, W.E., De-Kosky, S.T., 
DeKoskym, S.T., 2009. Amyloid image in mild cognitive impairment subtypes. 
Ann. Neurol. 65, 557e568. 

Wolz, R., Julkunen, V., Koikkalainen, J., Niskanen, E., Zhang, D.P., Rueckert, D., 
Soininen, H., Lötjönen, J., 2011. Multi-method analysis of MRI image in early 
diagnostics of Alzheimer’s disease. PLoS One 6, e25446. 

Wolz, R., Schwarz, A.J., Gray, K.R., Yu, P., Hill, D.L.G. Alzheimer’s Disease Neuro- 
image Initiative, 2016. Enrichment of clinical trial in MCI due to AD use 
marker of amyloid and neurodegeneration. Neurology 87, 1235e1241. 

Yang, X., Tan, M.Z., Qiu, A., 2012. CSF and brain structural image marker of the 
Alzheimer’s pathological cascade. PLoS One 7, e47406. 

Ye, J., Farnum, M., Yang, E., Verbeeck, R., Lobanov, V., Raghavan, N., Novak, G., 
DiBernardo, A., Narayan, V.A., 2012. Sparse learn and stability selection for 
predict MCI to AD conversion use baseline ADNI data. BMC Neurol. 12, 46. 

Yen, S.J., Lee, Y.S., 2009. Cluster-based under-sampling approach for imbalanced 
data distributions. Expert Syst. Appl. 36, 5718e5727. 

Young, J., Modat, M., Cardoso, M.J., Ashburner, J., Ourselin, S., 2012. Classification of 
Alzheimer’s disease patient and control with Gaussian processes. 2012 9th 
IEEE Int. Symp. Biomed. Imaging 1523e1526. 

Zhang, D., Shen, D., 2012. Predicting future clinical change of MCI patient use 
longitudinal and multimodal biomarkers. PLoS One 7, e33182. 

Zijdenbos, A.P., Forghani, R., Evans, A.C., 2002. Automatic “pipeline” analysis of 3-D 
MRI data for clinical trials: application to multiple sclerosis. IEEE Trans. Med. 
Imaging 21, 1280e1291. 

http://refhub.elsevier.com/S0197-4580(17)30229-4/sref19 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref19 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref19 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref20 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref20 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref20 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref20 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref21 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref21 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref21 
http://dx.doi.org/10.1109/ICCV.2007.4408839 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref23 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref23 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref23 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref23 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref24 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref24 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref24 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref25 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref25 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref25 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref26 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref26 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref26 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref26 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref26 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref26 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref27 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref27 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref27 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref28 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref28 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref28 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref29 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref29 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref29 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref30 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref30 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref30 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref30 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref31 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref31 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref31 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref31 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref31 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref31 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref32 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref32 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref32 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref32 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref33 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref33 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref33 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref33 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref33 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref33 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref33 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref34 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref34 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref34 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref35 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref35 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref35 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref35 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref35 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref36 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref36 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref36 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref36 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref37 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref37 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref37 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref37 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref37 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref37 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref38 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref38 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref38 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref38 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref38 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref38 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref38 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref39 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref39 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref39 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref72 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref72 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref72 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref72 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref40 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref40 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref40 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref40 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref41 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref41 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref41 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref42 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref42 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref42 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref42 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref43 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref43 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref43 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref43 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref43 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref44 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref44 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref44 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref44 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref45 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref45 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref45 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref45 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref45 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref46 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref46 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref46 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref46 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref47 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref47 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref47 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref47 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref48 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref48 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref49 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref49 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref49 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref49 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref50 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref50 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref50 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref50 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref51 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref51 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref51 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref51 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref52 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref52 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref52 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref52 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref52 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref53 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref53 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref53 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref54 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref54 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref54 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref54 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref54 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref55 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref55 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref55 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref55 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref56 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref56 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref56 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref56 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref57 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref57 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref57 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref57 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref58 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref58 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref58 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref59 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref59 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref59 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref59 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref59 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref60 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref60 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref60 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref60 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref60 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref61 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref61 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref61 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref61 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref61 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref62 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref62 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref62 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref62 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref63 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref63 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref63 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref63 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref63 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref64 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref64 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref64 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref65 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref65 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref65 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref65 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref66 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref66 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref67 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref67 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref67 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref68 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref68 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref68 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref69 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref69 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref69 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref69 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref70 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref70 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref71 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref71 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref71 
http://refhub.elsevier.com/S0197-4580(17)30229-4/sref71 

Identifying incipient dementia individual use machine learn and amyloid image 
1. Introduction 
2. Materials and method 
2.1. Subjects and data acquisition 
2.2. Image processing 
2.3. Subject classification 
2.4. Feature selection 
2.5. Prediction 
2.6. Performance evaluation and comparison 

3. Results 
4. Discussion 
Disclosure statement 
Acknowledgements 
Appendix A. Supplementary data 
References 


